Pictor® Holdings Inc.完成750万美元过桥融资，加速靶向蛋白质组学平台的商业化进程-动脉网

Pictor® Holdings Inc. Secures $7.5 Million Bridge Round to Accelerate Commercialization of Targeted Proteomic Platform

CISION 等信源发布 2026-06-30 22:47



可切换为仅中文







Investment brings Pictor's total capital raised to approximately $30 million, supporting expanded U.S. and international commercialization efforts

此次投资使Pictor的总融资额达到约3,000万美元，支持其扩大在美国及国际市场的商业化努力

CARLSBAD, Calif.

加利福尼亚州卡尔斯巴德

，

June 30, 2026

2026年6月30日

/PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform company headquartered in Carlsbad, California, today announced the closing of a $7.5 million bridge round of growth capital. The financing was supported by existing investors and will be used to expand commercial partnerships, scale platform development and manufacturing capabilities, and support translational studies across key human and animal health markets..

/美通社/ -- 总部位于加利福尼亚州卡尔斯巴德的全球靶向蛋白质组学平台公司 Pictor Holdings Inc. 今日宣布完成一轮750万美元的过桥融资。本轮融资由现有投资者支持，资金将用于拓展商业合作伙伴关系、扩大平台开发和制造能力，并支持在关键的人类和动物健康市场开展转化研究。

The bridge round brings Pictor's total capital raised to approximately $30 million. The investment builds on the company's commercial momentum following a strong first year at its U.S. headquarters, Pictor has launched seven commercial products, secured four strategic partnerships, and expanded its leadership team with the appointments of Terry Kelly, PhD, as Chief Operating Officer and Tim Shannon as Chief Financial Officer..

此轮过桥融资使 Pictor 的累计融资总额达到约 3,000 万美元。此次投资进一步巩固了公司在美国总部度过强劲首年后的商业发展势头。Pictor 已推出七款商业化产品，达成四项战略合作伙伴关系，并通过任命 Terry Kelly 博士为首席运营官、Tim Shannon 为首席财务官，扩充了其领导团队。

Pictor's targeted proteomic platform — comprising PictArray

Pictor 的靶向蛋白质组学平台——包括 PictArray

, PictImager

, and Pictorial

，以及《画报》

software — enables laboratories to analyze up to 20 protein targets from a single sample in under two hours. Designed to reduce cost and workflow complexity, the system delivers results at lower per-sample economics across pharma, reference laboratory, and animal health markets.

该软件使实验室能够在两小时内从单个样本中分析多达20种蛋白质靶标。该系统旨在降低成本和工作流程的复杂性，在制药、参考实验室和动物健康市场中以更低的单样本成本提供结果。

'Proteomic assays should not be limited to the largest, most specialized settings. Pictor's platform is designed to make protein insights more accessible, practical, and economical, so more partners can use them to improve health and wellness across people and animals. By helping labs generate more information from a single sample with fewer consumables, we also see an opportunity to support One Health and sustainability goals as adoption scales.'.

“蛋白质组学检测不应局限于规模最大、最专业化的机构。Pictor 的平台旨在使蛋白质洞察更易获取、更实用且更经济，从而让更多合作伙伴能够利用这些洞察来改善人类和动物的健康与福祉。通过帮助实验室在减少耗材使用的同时从单个样本中生成更多信息，我们也看到了在应用规模扩大的过程中支持‘同一健康’和可持续发展目标的机遇。”

— Jamie Platt, PhD, CEO and Co-founder, Pictor Holdings Inc.

— 杰米·普拉特博士，Pictor Holdings Inc. 首席执行官兼联合创始人

Proceeds from the bridge round will support the scaling of platform development and manufacturing capabilities, continued expansion of the company's partner network, and advancement of large-scale translational studies across priority markets. Pictor expects to enter licensing stages with multiple partners within the next 12 to 18 months..

本轮过桥融资所得将用于支持平台开发和制造能力的规模化扩张，持续扩大公司的合作伙伴网络，并推进在优先市场的大规模转化研究。Pictor 预计在未来12至18个月内与多家合作伙伴进入授权阶段。

Pictor is evaluating a U.S.-based Series A financing to support the next phase of growth, with plans to further expand commercial operations, platform development, and strategic partnerships. The bridge round strengthens the company's commercial position as it advances toward that milestone.

Pictor 正在评估一轮由美国主导的 A 轮融资，以支持其下一阶段的成长，计划进一步拓展商业运营、平台开发及战略合作伙伴关系。在此次迈向里程碑的过程中，过桥融资增强了公司的商业地位。

'The continued support of our existing investors reflects confidence in both the platform and the commercial model we've built around it. This capital positions Pictor to accelerate partnerships and scale operations as we advance toward our Series A.''

“现有投资者的持续支持，彰显了对我们平台及其周边商业模式的信心。这笔资金将使 Pictor 能够加速合作伙伴关系并扩大运营规模，从而推动我们向 A 轮融资迈进。”

— Tim Shannon, CPA, Chief Financial Officer, Pictor Holdings Inc.

— 蒂姆·香农，注册会计师，皮克托控股公司首席财务官

For more information or partnership inquiries, contact

如需更多信息或合作咨询，请联系

[email protected]

or visit

或访问

www.pictorproteomics.com

。

About Pictor Holdings Inc.

关于 Pictor Holdings Inc.

Pictor Holdings Inc. is a global targeted proteomic platform company headquartered in Carlsbad, California, with laboratory and commercial operations in New Zealand, Australia, and India. The company develops multi-analyte proteomic assay solutions for human and animal health research environments, enabling laboratories and biopharma partners to run more analytes, faster, at lower cost.

Pictor Holdings Inc. 是一家全球性的靶向蛋白质组学平台公司，总部位于加利福尼亚州卡尔斯巴德，在新西兰、澳大利亚和印度设有实验室和商业运营机构。该公司为人类和动物健康研究环境开发多分析物蛋白质组学检测解决方案，使实验室和生物制药合作伙伴能够以更低的成本、更快的速度运行更多的分析物。

Pictor's IP portfolio includes 16 patents, five pending, and seven registered trademarks. For more information, visit .

Pictor 的知识产权组合包括 16 项专利（其中 5 项正在申请中）以及 7 个注册商标。如需更多信息，请访问。

www.pictorproteomics.com

。

Media Contact

媒体联系人

Kelly Krueger

凯莉·克鲁格

Audacity Health on behalf of Pictor Holdings Inc.

Audacity Health 代表 Pictor Holdings Inc.

415-235-5031

[email protected]